Galantamine
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Galantamine: From Alzheimer’s Disease to Psychogenic Movement Disorders
One-Sentence Summary
Galantamine is a cholinesterase inhibitor conventionally used to treat cognitive impairment in Alzheimer’s disease. The TxGNN model predicts it may be effective for Psychogenic Movement Disorders, but this direction is currently supported by 0 clinical trials and 0 publications — it rests entirely on the model’s prediction score.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Alzheimer’s disease-related cognitive impairment (based on known global use; not TFDA-approved — drug is not marketed in Taiwan) |
| Predicted New Indication | Psychogenic Movement Disorders |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L5 |
| Taiwan Market Status | Not marketed (Not marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information, galantamine is a reversible acetylcholinesterase inhibitor that also allosterically modulates nicotinic acetylcholine receptors, and its efficacy in Alzheimer’s disease-related cognitive decline is well established clinically.
Psychogenic movement disorders, however, are by definition functional (non-organic) conditions — they are not caused by a structural or neurochemical cholinergic deficit, but by psychological/psychiatric mechanisms. This makes the biological rationale for a cholinergic drug quite different from galantamine’s original indication, where cholinergic neuronal loss is the core pathology.
The evidence pack’s own mechanistic assessment reflects this gap directly: it notes that support for this candidate consists solely of a high TxGNN prediction score, with no corroborating trials or literature, and that pharmacological intervention in a condition with a psychogenic (rather than organic cholinergic) basis has weak biological plausibility. This candidate should be interpreted as a hypothesis-generating signal only, not a mechanistically grounded lead.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
- Drug Interactions: 173 total interactions on record. Most flagged interactions are Moderate, largely with anticholinergic or GI-active agents (e.g., Famotidine, Ranitidine, Atropine, Cimetidine, Clarithromycin, Dicyclomine, Loperamide, Hyoscyamine, Trospium, Glycopyrronium — pharmacologically opposing galantamine’s cholinergic activity or affecting its metabolism). One interaction is flagged as Major: Bupropion.
(Key warnings and contraindications are not available in this evidence pack; please refer to the package insert for that information.)
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate has no clinical trial or literature support, is classified as Evidence Level L5 (model prediction only), and the mechanistic rationale itself argues against biological plausibility given the psychogenic (non-organic) nature of the target condition. Galantamine is also not currently marketed in Taiwan, so no local regulatory or safety-label data is available.
To proceed, the following is needed:
- Confirmed mechanism of action (MOA) documentation from DrugBank or another authoritative source
- TFDA/manufacturer package insert data (key warnings, contraindications) — currently a Blocking data gap per the evidence pack
- Any preclinical or case-level evidence directly linking cholinergic modulation to psychogenic movement disorder outcomes, before further investment in this specific indication
Note: Within this same evidence pack, two other predicted indications for galantamine carry meaningfully stronger evidence and may warrant separate evaluation — lingual-facial-buccal dyskinesia (i.e., tardive dyskinesia; L2, includes an RCT, decision stage S2) and extrapyramidal and movement disease (L3, includes 2 completed clinical trials, decision stage S1).
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.